文献速递前列腺癌

前列腺穿刺活检阴性但持续怀疑前列腺癌患者的风险分层:前瞻性队列研究中期分析

Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
PubMed 文献 · BJU Int · 2021-06-17

这项前瞻性队列研究纳入429例经直肠超声引导前列腺穿刺活检阴性但PSA升高、直肠指检可疑或家族史阳性的患者,基于多基因风险评分、年龄和家族史计算终生风险评分。中位随访4年,高危及标危组前列腺癌检出率分别为42%和18%,但两组累积发病率无统计学显著差异,提示该风险评分在此类患者中的分诊预后价值有限。

要点

  • 终生风险评分将88%患者归为标危组,12%归为高危组。
  • 高危组前列腺癌检出率42%,标危组18%,但累积发病率无显著差异。
  • 该评分未能显著改善穿刺阴性持续怀疑前列腺癌患者的分诊。

核心结论

  • 在4年随访中,基于多基因风险评分、年龄和家族史的前列腺癌终生风险评分对穿刺阴性但持续怀疑前列腺癌患者未显示出显著的分诊预后价值。

研究设计与样本

  • 前瞻性临床研究,纳入429例经直肠超声引导前列腺穿刺活检阴性但PSA升高、直肠指检可疑和/或前列腺癌家族史阳性的患者并进行风险评分。
  • 患者接受每年一次包括PSA检测的随访,最长4年,根据风险评分和医患意愿选择进行多参数磁共振成像和/或前列腺穿刺活检。

主要发现

  • 风险评分后,376/429(88%)归入标危组(终生风险<30%),53/429(12%)归入高危组(终生风险≥30%)。
  • 高危组随访中接受更多穿刺活检和多参数磁共振成像检查。
  • 共检出前列腺癌89/429(21%),标危组67/376(18%),高危组22/53(42%)。
  • 随访4年后,标危组和高危组前列腺癌累积发病率无统计学显著差异。
  • 目前仍有67/429(16%)患者在该进行中的研究中继续随访。

关键数值与推荐

  • 终生风险评分基于33个单核苷酸多态性的多基因风险评分、年龄和前列腺癌家族史计算。
  • 风险分组阈值:标危组终生风险<30%,高危组≥30%。

临床怎么用

  • 对于穿刺阴性但持续怀疑前列腺癌的患者,该终生风险评分尚不足以作为分诊工具指导临床决策。

局限性

  • 研究为中期分析,部分患者仍在随访中(67/429,16%),随访时间最长4年。
  • 随访方案根据风险评分和医患意愿个体化制定,可能导致检测偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether a risk score for prostate cancer (PCa) lifetime risk can be used to optimise triaging of patients with a negative prostate biopsy, but under sustained suspicion of PCa. PATIENTS AND METHODS: In this prospective clinical study, we included, and risk scored patients who had a PCa-negative transrectal ultrasonography (TRUS)-guided prostate biopsy, but elevated prostate-specific antigen (PSA), a suspicious prostate digital rectal examination and/or a positive family history (FH) of PCa. The risk score estimated individual lifetime risk of PCa, based on a polygenic risk score (33 single nucleotide polymorphisms), age, and FH of PCa. Patients were followed, under urological supervision, for up to 4 years with annual controls, always including PSA measurements. Multiparametric magnetic resonance imaging (mpMRI) and/or prostate biopsy was performed at selected annual controls depending on risk score and at the urologist's/patient's discretion, which means that the follow-up differed based on the risk score. RESULTS: We included 429 patients. After risk scoring, 376/429 (88%) patients were allocated to a normal-risk group (<30% PCa lifetime risk) and 53/429 (12%) to a high-risk group (≥30% PCa lifetime risk). The high-risk group had significantly different follow-up, with more biopsy and mpMRI sessions compared to the normal-risk group. PCa was detected in 89/429 (21%) patients, with 67/376 (18%) patients diagnosed in the normal-risk group and 22/53 (42%) in the high-risk group. There was no statistically significant difference in the cumulative incidence of PCa between the normal-risk group and the high-risk group after 4 years of follow-up. Currently, 67/429 (16%) patients are still being followed in this ongoing study. CONCLUSION: In a 4-year perspective, our PCa lifetime risk score did not demonstrate significant prognostic value for triaging patients, with a negative TRUS-guided biopsy and sustained suspicion of PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Sandahl M, Pedersen BG, Ulhøi BP, et al. Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study. BJU Int. 2021. PMID: 33964113. doi:10.1111/bju.15443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。